Antimycobacterial potential of Mycobacteriophage under disease-mimicking conditions
Abstract
Antibiotic resistance continues to be a major global health risk with an increase in multi-drug resistant infections seen across nearly all bacterial diseases. Mycobacterial infections such as Tuberculosis (TB) and Non-Tuberculosis infections have seen a significant increase in the incidence of multi-drug resistant and extensively drug-resistant infections. With this increase in drug-resistant Mycobacteria, mycobacteriophage therapy offers a promising alternative. However, a comprehensive study on the infection dynamics of mycobacteriophage against their host bacteria and the evolution of bacteriophage (phage) resistance in the bacteria remains elusive. We aim to study the infection dynamics of a phage cocktail against Mycobacteria under various pathophysiological conditions such as low pH, low growth rate and hypoxia. We show that mycobacteriophages are effective against M. smegmatis under various conditions and the phage cocktail prevents emergence of resistance for long durations. Although the phages are able to amplify after infection, the initial multiplicity of infection plays an important role in reducing the bacterial growth and prolonging efficacy. Mycobacteriophages are effective against antibiotic-resistant strains of Mycobacterium and show synergy with antibiotics such as rifampicin and isoniazid. Finally, we also show that mycobacteriophages are efficient against M. tuberculosis both under lag and log phase for several weeks. These findings have important implications for developing phage therapy for Mycobacterium.
02 /Specification & Classification
Click any tag to browse matching papers- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Activity of a three-phage combination against Mycobacterium tuberculosis in disease-relevant conditions
Saskia Janssen, Sasha E. Larsen, … Jakko van Ingen·bioRxiv·May 11, 2026
- Aminoglycoside antibiotics inhibit mycobacteriophage infection
Z. Jiang, J. Wei, … Y. Li·AntibioticsPeer-reviewed·Oct 19, 2020
- Comparative study on the virulence of mycobacteriophages
Ilaria Rubino, Carlos A. Guerrero-Bustamante, … Dominic Sauvageau·Journal of VirologyPeer-reviewed·May 21, 2025
- Inactivating conditions of therapeutic mycobacteriophages
Andrew G. Wiggins, Umar Chaudhry, … Miriam Braunstein·Microbiology SpectrumPeer-reviewed·Feb 11, 2026
- Mycobacteriophage TM4 requires XylR for successful infection in Mycobacterium smegmatis mc2155
Annesha Adhikari, Tejan Lodhiya, … Raju Mukherjee·bioRxiv·May 17, 2026
- Genome announcement and analysis of five new mycobacteriophages belonging to the F, G, K, and P clusters
Ritu Arora, Ritam Das, … Urmi Bajpai·bioRxiv·Feb 15, 2024